|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study and additional publications | Intervention (I) and control groups (C) | No of pa-tients | Disease duration (years) | No of swollen joints | No of tender joints | HAQ | Previous MTX use | MTX dose (mg/vk) | Primary clinical outcome | RCT duration  |
| **Abe 200649** | I1: 3mg/kg Inf + MTX | 49 | 9,1 | 15,1 | 19 | n/a | Yes | 7,12 | ACR 20 14wk | 14 weeks |
|  | I2: 10mg/kg Inf+ MTX | 51 | 7,1 | 13,2 | 18,7 | n/a | Yes | 7,12 |  |  |
|  | C1: MTX + placebo  | 47 | 7,5 | 13,5 | 17,8 | n/a | Yes | 7,42 |  |  |
|  | *Inf at weeks 0, 2 and 6* |  |  |  |  |  |  |  |  |  |
| **Maini 199953** | I1: Inf 3mg/kg+MTX e8w | 86 | 10 | 22 | 32 | 1.8 | Yes | 16 | ACR 20 30wk | 30 weeks |
| Lipsky 200051 | I2: Inf 3mg/kg+MTX e4w | 86 | 9 | 21 | 31 | 1.7 | Yes | 16 |  |  |
| Maini 200452 | I3: Inf 10mg/kg+MTX e8w | 87 | 11 | 23 | 32 | 1.7 | Yes | 16 |  |  |
| Smolen 200556 | I4: Inf 10mg/kg+MTX e4w | 81 | 12 | 24 | 34 | 1.7 | Yes | 17 |  |  |
|  | C1: Placebo + MTX | 88 | 11 | 21 | 31 | 1.7 | Yes | 16 |  |  |
| **Quinn 200554** | I1: Inf 3mg/kg+MTX | 10 | 0,62 | n/a | n/a | 1,3 | No | 15 | None | 12 months |
|  | C1: Placebo + MTX | 10 | 0,62 |  |  |  |  |  |  |  |
|  | *Inf at weeks 0, 2 and 6, then every 8 weeks* |  |  |  |  |  |  |  |  |  |
| **Schiff 200855** | I1: Inf 3mg/kg + MTX | 165 | 7,3 | 20,3 | 31,7 | 1,7 | Yes | 16,3 | DAS 28 6kk (abatacept vs.infliximab) | 12 months5  |
| Bessette 200750 | C1: Placebo + MTX | 110 | 4 | , | 8 | 20,1 | 30,3 | 1,8 |  |  |
| Van Vollen-hoven 200859 | *Inf at weeks 0, 2 and 6, then every 8 weeks* |  |  |  |  |  |  |  |  |  |
| **St. Clair 200458** | I1: Inf 3mg/kg+ MTX | 359 | 0,8 | 21 | 32 | No | 1,5 | 15,5 | 54 weeks | ACR-N 54 wk |
| Smolen 200657 | I2: Inf 10mg/kg + MTX | 363 | 0,9 | 22 | 33 | 1,5 | No | 14,9 |  |  |
|  | C1: Placebo + MTX | 282 | 0,9 | 22 | 34 | 1,5 | No | 15,1 |  |  |
|  | *Inf at weeks 0, 2 and 6, then every 8 weeks* |  |  |  |  |  |  |  |  |  |
| **Bathon 200061** | I1: 25mg Eta | 207 | 1 | 24 | 31 | n/a | No |  | ACR-N 0-6mo | 12 months |
| Bathon 200360 | C1: MTX + placebo | 217 | 1 | 24 | 30 | n/a | No | 19 |  |  |
| Genovese 200264 | *Eta twice a week* |  |  |  |  |  |  |  |  |  |
| **Emery 200862** | I1: Eta 50mg +  | 274 | 0,733 | 17,1 | 25,1 | 1,7 | No | 16,8 | DAS remission 52wk | 52 weeks |
| Emery 201063 | C1: MTX + placebo | 268 | 0,775 | 17,6 | 24,8 | 1,6 | No | 19.6 (wk 8) |  |  |
|  | *Eta once a week* |  |  |  |  |  |  |  |  |  |
| **Keystone 200466** | I1: Eta 50mg | 214 | 9 | 19.2 | 263 | 1,4 | No/yes | 14.3(53%) | ACR 20 8 wk | 16 weeks |
|  | I2: Eta 25mg | 153 | 8,2 | 19.2 | 29.23 | 1,4 | No/yes | 15.0(52%) |  |  |
|  | C1: PlaceboSome of the patients on MTX | 53 | 10,8 | 19.2 | 24.63 | 1,4 | No/yes | 13.8(55%) |  |  |
| **Klareskog 200467** | I1: Eta 25mg | 223 | 6,3 | 23,0 | 35 | 1.7 | No/yes | 16,9 | ACR-N wk 24 | 52 weeks |
| Kavanaugh 200865 | I2: Eta 25mg + MTX | 231 | 6,8 | 22,1 | 34,2 | 1.8 | No/yes | 17,2 |  |  |
| Van der Heijde 200671 | C1: Placebo + MTX | 228 | 6,8 | 22,6 | 33,1 | 1.7 | No/yes | (wk 8) |  |  |
| Heijde 200770 | *Eta twice a week* |  |  |  |  |  |  |  |  |  |
| **Lan 200468** | I1: Eta 25mg + MTX | 29 | n/a | 13,211 | 14,031 | 0,99 | Yes | 12,5-20 | SJC and TJC  | 12 weeks |
|  | C1: Placebo + MTX | 29 | n/a | 14.451 | 16.001 | 1,23 | Yes | 12,5-20 |  |  |
|  | *Eta twice a week* |  |  |  |  |  |  |  |  |  |
| **Moreland 199969** | I1: Eta 25mg | 78 | 11 | 25 | 33 | 1,6 | No/yes |  | ACR 20 and 50 3 and 6mo | 6 months |
|  | C1: Placebo | 80 | 12 | 25 | 35 | 1,7 | No/yes |  |  |  |
|  | *Eta twice 2 week* |  |  |  |  |  |  |  |  |  |
| **Weinblatt 199972** | I1: Eta 25mg + MTX | 59 | 13 | 204 | 284 | 1,54 | Yes | 19 | Endpoints not specified | 24 weeks |
|  | C1: Placebo + MTX | 30 | 13 | 174 | 284 | 1,54 | Yes | 18 |  |  |
|  | *Eta twice a week* |  |  |  |  |  |  |  |  |  |
| **Breedveld 200673** | I1: Ada 40 mg + MTX | 274 | 0,7 | 21,8 | 31,8 | 1,6 | No | 0 | ACR 50 12mo | 2 years |
|  |  I2: Ada 40 mg + placebo | 268 | 0,7 | 21,1 | 30,7 | 1,5 | No | 16.3 |  |  |
|  | C1: MTX + placebo | 257 | 0,8 | 22,1 | 32,3 | 1,5 | No | 16.9 |  |  |
|  | *Ada every other week* |  |  |  |  |  |  |  |  |  |
| **Chen 200974** | I1: Ada 40mg + MTX | 35 | 6,2 | 21,9 | 32,5 | 1,7 | Yes | 10-15 | ACR 20 12wk | 12 weeks |
|  | C1: MTX + placebo | 12 | 8,3 | 24,1 | 37,2 | 1,8 | Yes | 10-15 |  |  |
|  | *Ada every other week* |  |  |  |  |  |  |  |  |  |
| **Keystone 200477** | I1: Ada 40mg + MTX | 207 | 11 | 19,3 | 27,3 | 1,45 | Yes | 16.7 | ACR 20 wk 24 | 52 weeks |
| Jamal 200975 | C1: Placebo + MTX | 200 | 10,9 | 19,0 | 28,1 | 1,48 | Yes | 16.7 | HAQ wk 54 |  |
| Keystone 200376 | *Ada every other week* |  |  |  |  |  |  |  |  |  |
| **Kim 200778** | I1: Ada 40mg + MTX  | 65 | 6,8 | 12,2 | 19,2 | 1,4 | Yes | 16,62 | ACR 20 wk 24 | 24 weeks |
|  | C1: Placebo + MTX | 63 | 6,9 | 12,8 | 20,3 | 1,3 | Yes | 16,32 |  |  |
| **Miyasaka 200879** | I1: Ada 40mg | 91 | 9,9 | 19,1 | 24,4 | 1,64 | No/yes |  | ACR 20 wk24 | 24 weeks |
|  | I2: Ada 80mg | 87 | 9,5 | 20,8 | 24,9 | 1,77 | No/yes |  |  |  |
|  | C1: Placebo | 87 | 8,4 | 19,3 | 23,7 | 1,39 | No/yes |  |  |  |
|  | *Ada every other week* |  |  |  |  |  |  |  |  |  |
| **Van de Putte 200380** | I1: Ada 40mg | 70 | 10 | 18,7 | 31,0 | 1,74 | No/yes |  | ACR 20 12wk | 12 weeks |
|  | I2: Ada 80mg | 72 | 10,1 | 19,6 | 32,5 | 1,66 | No/yes |  |  |  |
|  | C1: Placebo | 70 | 9,4 | 19,8 | 30,9 | 1,63 | No/yes |  |  |  |
|  | *Ada every other week* |  |  |  |  |  |  |  |  |  |
| **Van de Putte 200481** | I1: Ada 40mg *eow* | 113 | 10,6 | 20,5 | 33,7 | 1,83 | No/yes |  | ACR 20 | 26 weeks |
|  | I2: Ada 40mg *weekly* | 103 | 11,9 | 19,3 | 33,8 | 1,84 | No/yes |  |  |  |
|  | C1: Placebo | 110 | 11,6 | 19,8 | 35,5 | 1,88 | No/yes |  |  |  |
| **Weinblatt 200382** | I1: Ada 40mg + MTX | 67 | 12,2 | 17,3 | 28,0 | 1,55 | Yes | 16,4 | ACR 20 24wk | 24 weeks |
|  | I2: Ada 80mg + MTX | 73 | 12,8 | 17,0 | 30,3 | 1,55 | Yes | 17,2 |  |  |
|  | C1: Placebo + MTX | 62 | 11,1 | 16,9 | 28,7 | 1,64 | Yes | 16,5 |  |  |
|  | *Ada every other week* |  |  |  |  |  |  |  |  |  |
| **Emery 200983** | I1: Gol 100mg+placebo | 159 | 4.1 | 12 | 24,5 | 1,7 | No |  | ACR 50 24wk | 52 weeks |
|  | I2: Gol 50mg+MTX | 159 | 3.5 | 13 | 26 | 1,5 | No | 19,2 |  |  |
|  | I3: Gol 100mg+MTX | 159 | 3.6 |  | 14 | 26 | 1,6 | No |  |  |
|  | C1: MTX + placebo | 160 | 2.9 | 11 | 25,5 | 1,5 | No | 19,1 |  |  |
|  | *Gol every 4 weeks* |  |  |  |  |  |  | (wk 23) |  |  |
| **Kay 200884** | I1: Gol 50mg+MTX (eow) | 35 | 8,2 | 14 | 28 | 1,7 | Yes | ≥10 | ACR 20 16wk | 52 weeks |
|  | I2: Gol 50mg+MTX (e4w) | 34 | 8,2 | 14 | 28 | 1,6 | Yes | ≥10 |  |  |
|  | I3: Gol 100mg+MTX (eow) | 34 | 6,3 | 20 | 32 | 1,8 | Yes | ≥10 |  |  |
|  | I4: Gol 100mg+MTX (e4w) | 34 | 9,0 | 14 | 22 | 1,3 | Yes | ≥10 |  |  |
|  | C1: MTX + placebo | 35 | 5,6 | 13 | 22 | 1,3 | Yes | ≥10 |  |  |
| **Keystone 200985** | I1: Gol 100mg + placebo | 133 | 5,9 | 11 | 22 | 1,38 | Yes | 15 | ACR 20 wk 14 | 52 weeks |
|  | I2: Gol 50mg + MTX | 89 | 4,5 | 13 | 26 | 1,38 | Yes | 15 |  |  |
|  | I3: Gol 100mg + MTX | 89 | 6,7 | 12 | 23 | 1,38 | Yes | 15 |  |  |
|  | C1: MTX + placebo | 133 | 6,5 | 12 | 21 | 1,25 | Yes | 15 |  |  |
|  | *Gol every 4 weeks* |  |  |  |  |  |  |  |  |  |
| **Fleischmann 200986** | I1: Cer 400mg  | 111 | 8,7 | 21,2 | 29,6 | 1,4 | No/yes |  | ACR 20 24wk | 24 weeks |
|  | C1: Placebo | 109 | 10,4 | 19,9 | 28,3 | 1,6 | No/yes |  |  |  |
|  | *Cer every 4 weeks* |  |  |  |  |  |  |  |  |  |
| **Keystone 200887** | I1: Cer 200mg + MTX | 393 | 6,1 | 21,7 | 30,8 | 1,7 | Yes | 13,62 | ACR 20 wk 24 | 52 weeks |
|  | I2: Cer 400mg + MTX | 390 | 6,2 | 21,5 | 31,1 | 1,7 | Yes | 13,62 |  |  |
|  | C1: MTX + placebo | 199 | 6,2 | 21,2 | 29,8 | 1,7 | Yes | 13,42 |  |  |
| **Smolen 200988** | I1: Cer 200mg + MTX | 246 | 6,1 | 20,5 | 30,1 | 1,6 | Yes | 12,52 | ACR 20 24wk | 24 weeks |
|  | I2: Cer 400mg + MTX | 246 | 6,5 | 21,0 | 30,0 | 1,6 | Yes | 12,62 |  |  |
|  | C1: Placebo + MTX | 127 | 5,6 | 21,9 | 30,4 | 1,6 | Yes | 12,22 |  |  |
|  | *Cer every other week* |  |  |  |  |  |  |  |  |  |